Adaptimmune Therapeutics Stock Soars 14% on Portfolio Sale

Adaptimmune Therapeutics' stock surged 14% in pre-market trading on July 29, 2025, reflecting significant investor interest and potential market shifts.

Adaptimmune Therapeutics has recently made strategic moves that have impacted its stock performance. The company announced the sale of its cell therapy portfolio, including key assets like TECELRA, lete-cel, afami-cel, and uza-cel, to US WorldMeds for $55 million. This decision is part of a broader restructuring effort aimed at optimizing the company's operations and financial health.

Following the announcement of the sale agreement, Adaptimmune's stock experienced a significant decline, trading down 65% to 12 cents per share early Monday afternoon. This drop was likely due to investor concerns about the company's future direction and the potential impact of the asset sale on its long-term prospects.

Despite the recent volatility, analysts remain optimistic about Adaptimmune's future. According to six analysts, the average rating for ADAP stock is "Buy," with a 12-month stock price target of $1.35, representing a potential increase of 1,250.00% from the latest trading price. This positive outlook suggests that investors may see value in the company's remaining assets and future growth potential.